Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation

Citation
Y. Maeda et al., Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation, BR J HAEM, 105(1), 1999, pp. 295-302
Citations number
30
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
BRITISH JOURNAL OF HAEMATOLOGY
ISSN journal
00071048 → ACNP
Volume
105
Issue
1
Year of publication
1999
Pages
295 - 302
Database
ISI
SICI code
0007-1048(199904)105:1<295:MOHHAA>2.0.ZU;2-W
Abstract
Herpesviruses frequently cause serious complications after allogeneic bone marrow transplantation (allo-BMT). Recent studies have shown more rapid imm une reconstitution after allogeneic peripheral blood stem cell transplantat ion (allo-PBSCT) compared with allo-BMT. However, it has not been clarified whether the improved immune reconstitution after allo-PBSCT is associated with a lower incidence of herpesvirus infections. We monitored the emergenc e of Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 6 ( HHV-6) and HHV-7 DNA by a nested-double polymerase chain reaction in periph eral blood leucocytes from 22 allo-BMT and 16 allo-PBSCT patients, Each vir us had an unique temporal profile of detection. HHV-6 DNA was detected most frequently at 3 weeks after transplantation, whereas CMV and EBV DNA were detected later (2-3 months). Detection rates of HHV-6 DNA at 3 and 4 weeks after allo-BMT were significantly higher than those after allo-PBSCT (9/16 v 2/13 at 3 weeks, P< 0.01; 10/21 v 1/15 at 4 weeks, P<0.01). Detection rat es of the other three herpesviruses after the two types of allogeneic trans plantation were not significantly different throughout observation period. Furthermore, detection of HHV-6 DNA within the first 4 weeks was associated with delayed platelet engraftment after both allo-BMT and allo-PBSCT (P<0. 01). These results suggest an advantage for allo-PBSCT over allo-BMT in ter ms of suppression of HHV-6 reactivation and prevention of subsequent compli cations.